Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share (the "Shares")
-
Shares outstanding
-
93.8M
-
Number of holders
-
113
-
Total 13F shares, excl. options
-
51.4M
-
Shares change
-
+555K
-
Total reported value, excl. options
-
$1.01B
-
Value change
-
+$12.5M
-
Number of buys
-
60
-
Number of sells
-
-38
-
Price
-
$19.64
Significant Holders of Crinetics Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (the "Shares") (CRNX) as of Q3 2022
128 filings reported holding CRNX - Crinetics Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (the "Shares") as of Q3 2022.
Crinetics Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (the "Shares") (CRNX) has 113 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 51.4M shares
of 93.8M outstanding shares and own 54.81% of the company stock.
Largest 10 shareholders include DRIEHAUS CAPITAL MANAGEMENT LLC (5.63M shares), PERCEPTIVE ADVISORS LLC (5.32M shares), BlackRock Inc. (3.75M shares), BVF INC/IL (3.68M shares), ORBIMED ADVISORS LLC (3.2M shares), FMR LLC (2.68M shares), WELLINGTON MANAGEMENT GROUP LLP (2.63M shares), VANGUARD GROUP INC (2.36M shares), Bain Capital Life Sciences Investors, LLC (2.31M shares), and STATE STREET CORP (1.81M shares).
This table shows the top 113 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.